Simposio- Cáncer de Páncreas: retos y perspectivas futuras (Sesiones I y II)

The symposium provides a comprehensive overview of current research in pancreatic cancer, with a strong emphasis on molecular mechanisms and translational approaches. The presentations are scientifically rigorous, drawing on recent data from leading laboratories. The speakers are well-established researchers, and their talks reflect the latest findings in the field. The content is highly technical, assuming a specialized audience, but the information is presented clearly and logically. The symposium successfully highlights the shift towards targeted therapies, particularly KRAS inhibitors, which represent a significant advancement over traditional chemotherapy. The use of single-cell sequencing and genetic mouse models demonstrates the cutting-edge methodologies being employed. However, the symposium is limited by its short duration, and some topics are only briefly touched upon. The lack of discussion on clinical trial results and patient outcomes is a notable omission. Additionally, the presentations are largely focused on preclinical studies, with limited emphasis on the challenges of translating these findings to clinical practice. The symposium also does not address the economic and accessibility issues associated with new therapies. Despite these limitations, the symposium offers valuable insights into the future directions of pancreatic cancer research and treatment. The inclusion of diverse perspectives, from basic science to clinical application, provides a holistic view of the field. The symposium is a valuable resource for researchers and clinicians seeking to stay abreast of the latest developments in pancreatic cancer.

The title accurately reflects the content, which is a symposium covering challenges and future perspectives in pancreatic cancer across two sessions.

8/10

The symposium features presentations by leading researchers in pancreatic cancer, including experts from CNIO, IDIBELL, and CRUK Scotland Institute. The content is based on recent research findings and ongoing clinical trials, with a strong emphasis on molecular mechanisms and therapeutic advances. The talks are technical and assume a specialized audience, but the information is credible and up-to-date.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction and welcome by Mariano Barbacid, highlighting the golden age of pancreatic cancer research.
• 10:00Meritxell Rovira presents on pancreatic ductal cell plasticity and single-cell sequencing.
• 1:00:00Bruno Sainz discusses advances in preclinical models of pancreatic cancer.
• 1:30:00Justo P. Castaño talks about dysregulated splicing in pancreatic cancer.
• 2:00:00Francisco X Real presents on genetic mouse models for precision prevention.
• 2:30:00Jen Morton discusses microenvironmental mechanisms of treatment resistance.
• 2:50:00Vasiliki Liaki presents combined targeted therapy achieving total tumor regression.

• Fundacion Areces — Organizer of the symposium and funding source.
• CNIO (Spanish National Cancer Research Centre) — Several speakers are affiliated with CNIO, including Mariano Barbacid and Francisco X Real.
• IDIBELL (Bellvitge Biomedical Research Institute) — Meritxell Rovira is affiliated with IDIBELL.
• CRUK Scotland Institute — Jen Morton is affiliated with CRUK Scotland Institute.

• Pancreatic Cancer Action Network — Provides information on pancreatic cancer research and advocacy.
• American Cancer Society — General information on pancreatic cancer.